TVTX
VENTE TOTALE: 10 000 titres (~628 974,00 $ US)
- Insiders
- LYONS GARY A
- Total bought
- —
- Total sold
- $628,974
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-21
TVTX presents a structurally weak risk profile: despite improving gross margins and FILSPARI revenue momentum, the company remains cash-flow negative with severe interest coverage deficits and high leverage, making it…
The first sentence of the analysis written for TVTX on 2026-08-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | |
| Ebit Margin | -7.9% | -132.7% | -251.2% | -292.5% | -149.6% | |
| Ebitda Margin | 4.5% | -114.0% | -224.6% | -273.5% | -139.9% | |
| Operating Profit Margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | |
| Pretax Profit Margin | -10.0% | -137.5% | -259.0% | -302.5% | -164.5% | |
| Continuous Operations Profit Margin | -10.2% | -137.5% | -259.1% | -302.8% | -164.8% | |
| Net Profit Margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | |
| Bottom Line Profit Margin | -10.2% | -137.9% | -76.7% | -254.4% | -136.6% | |
| Current Ratio | 2.736 | 2.076 | 3.467 | 3.422 | 4.697 | |
| Quick Ratio | 2.700 | 2.045 | 3.414 | 3.390 | 4.638 | |
| Solvency Ratio | 0.072 | -0.520 | -0.124 | -0.409 | -0.353 | |
| Cash Ratio | 0.582 | 0.292 | 0.327 | 0.434 | 1.336 | |
| Price To Earnings Ratio | -68.232 | -4.270 | -5.993 | -4.812 | -10.312 | |
| Price To Earnings Growth Ratio | 0.791 | -0.025 | 0.091 | -0.107 | 0.667 | |
| Forward Price To Earnings Growth Ratio | 0.791 | -0.025 | 0.091 | -0.107 | 0.667 | |
| Price To Earnings Diluted Ratio | -68.232 | -4.270 | -5.993 | -4.812 | -10.312 | |
| Price To Earnings Diluted Growth Ratio | 0.791 | -0.025 | 0.091 | -0.107 | 0.667 | |
| Price To Book Ratio | 29.686 | 23.262 | 3.325 | 31.291 | 6.147 | |
| Price To Sales Ratio | 6.946 | 5.894 | 4.597 | 12.250 | 14.087 | |
| Price To Free Cash Flow Ratio | -167.319 | -4.058 | -2.076 | -6.246 | -47.690 | |
| Price To Operating Cash Flow Ratio | 90.218 | -5.787 | -2.384 | -7.198 | -125.554 | |
| Debt To Assets Ratio | 0.543 | 0.676 | 0.513 | 0.606 | 0.337 | |
| Debt To Equity Ratio | 2.863 | 6.798 | 2.016 | 9.509 | 0.867 | |
| Debt To Capital Ratio | 0.741 | 0.872 | 0.668 | 0.905 | 0.464 | |
| Long Term Debt To Capital Ratio | 0.731 | 0.840 | 0.653 | 0.898 | 0.429 | |
| Financial Leverage Ratio | 5.270 | 10.057 | 3.929 | 15.696 | 2.571 | |
| Working Capital Turnover Ratio | 1.988 | 0.712 | 0.371 | 0.273 | 0.340 | |
| Operating Cash Flow Ratio | 0.236 | -1.183 | -1.574 | -1.310 | -0.119 | |
| Operating Cash Flow Sales Ratio | 0.077 | -1.018 | -1.928 | -1.702 | -0.112 | |
| Free Cash Flow Operating Cash Flow Ratio | -0.539 | 1.426 | 1.149 | 1.152 | 2.633 | |
| Debt Service Coverage Ratio | 1.975 | -3.329 | -28.804 | -27.214 | -9.393 | |
| Interest Coverage Ratio | -5.845 | -28.960 | -34.245 | -29.037 | -10.132 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -3.458 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.115 | -0.591 | -0.692 | -0.457 | -0.056 | |
| Capital Expenditure Coverage Ratio | 0.650 | -2.346 | -6.733 | -6.567 | -0.612 | |
| Dividend Paid And Capex Coverage Ratio | 0.650 | -2.346 | -6.733 | -6.567 | -0.612 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 164.033 | -6.462 | -3.109 | -5.633 | -10.590 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.9% | ▲1.2% | ▲1.9% |
| Ebit Margin | -7.8% | ▲124.8% | ▲158.9% |
| Ebitda Margin | 4.5% | ▲118.5% | ▲154.0% |
| Operating Profit Margin | -12.8% | ▲126.1% | ▲159.7% |
| Pretax Profit Margin | -10.0% | ▲127.4% | ▲164.7% |
| Continuous Operations Profit Margin | -10.2% | ▲127.3% | ▲164.7% |
| Net Profit Margin | -5.2% | ▲132.7% | ▲117.0% |
| Bottom Line Profit Margin | -10.2% | ▲127.7% | ▲112.9% |
| Current Ratio | 2.736 | ▲0.661 | ▼-0.543 |
| Quick Ratio | 2.700 | ▲0.655 | ▼-0.538 |
| Solvency Ratio | 0.072 | ▲0.591 | ▲0.339 |
| Cash Ratio | 0.582 | ▲0.290 | ▼-0.012 |
| Price To Earnings Ratio | -68.232 | ▼-63.962 | ▼-49.508 |
| Price To Earnings Growth Ratio | 0.791 | ▲0.816 | ▲0.507 |
| Forward Price To Earnings Growth Ratio | 0.791 | ▲0.816 | ▲0.507 |
| Price To Earnings Diluted Ratio | -68.232 | ▼-63.962 | ▼-49.508 |
| Price To Earnings Diluted Growth Ratio | 0.791 | ▲0.816 | ▲0.507 |
| Price To Book Ratio | 29.686 | ▲6.424 | ▲10.944 |
| Price To Sales Ratio | 6.946 | ▲1.053 | ▼-1.808 |
| Price To Free Cash Flow Ratio | -167.319 | ▼-163.261 | ▼-121.841 |
| Price To Operating Cash Flow Ratio | 90.218 | ▲96.005 | ▲100.359 |
| Debt To Assets Ratio | 0.543 | ▼-0.133 | ▲0.008 |
| Debt To Equity Ratio | 2.863 | ▼-3.935 | ▼-1.548 |
| Debt To Capital Ratio | 0.741 | ▼-0.131 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.731 | ▼-0.109 | ▲0.021 |
| Financial Leverage Ratio | 5.270 | ▼-4.786 | ▼-2.234 |
| Working Capital Turnover Ratio | 1.988 | ▲1.276 | ▲1.252 |
| Operating Cash Flow Ratio | 0.236 | ▲1.419 | ▲1.026 |
| Operating Cash Flow Sales Ratio | 0.077 | ▲1.095 | ▲1.014 |
| Free Cash Flow Operating Cash Flow Ratio | -0.539 | ▼-1.965 | ▼-1.703 |
| Debt Service Coverage Ratio | 1.975 | ▲5.305 | ▲15.328 |
| Interest Coverage Ratio | -5.845 | ▲23.114 | ▲15.799 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲3.458 | ▲0.692 |
| Operating Cash Flow Coverage Ratio | 0.115 | ▲0.706 | ▲0.451 |
| Capital Expenditure Coverage Ratio | 0.650 | ▲2.996 | ▲3.772 |
| Dividend Paid And Capex Coverage Ratio | 0.650 | ▲2.996 | ▲3.772 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 164.033 | ▲170.494 | ▲136.385 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.41B | $1.37B | $667.7M | $1.34B | $1.86B | |
| Enterprise value | $3.64B | $1.72B | $1.01B | $1.69B | $1.95B | |
| EV / Sales | 7.43x | 7.37x | 6.98x | 15.41x | 14.82x | |
| EV / Op. cash flow | 96.46x | -7.23x | -3.62x | -9.05x | -132.06x | |
| EV / Free cash flow | -178.89x | -5.07x | -3.15x | -7.86x | -50.16x | |
| EV / EBITDA | 164.03x | -6.46x | -3.11x | -5.63x | -10.59x | |
| Net debt / EBITDA | 10.61x | -1.29x | -1.06x | -1.16x | -0.52x | |
| Current ratio | 2.74x | 2.08x | 3.47x | 3.42x | 4.70x | |
| Income quality | -1.48x | 0.74x | 0.74x | 0.56x | 0.07x | |
| Graham net-net | -$1 | -$2 | -$0 | -$3 | $2 | |
| Tax burden | 51.8% | 100.3% | 29.6% | 84.1% | 83.0% | |
| Interest burden | 127.9% | 103.6% | 103.1% | 103.4% | 110.0% | |
| Working capital | $277.7M | $216.0M | $438.9M | $344.3M | $458.7M | |
| Invested capital | $405.4M | $339.6M | $568.9M | $471.4M | $641.4M | |
| Return on assets | -4.2% | -54.1% | -14.1% | -41.4% | -23.2% | |
| Operating ROA | -10.5% | -46.8% | -53.1% | -44.1% | -28.8% | |
| Return on tangible assets | -5.2% | -65.6% | -16.3% | -48.4% | -28.7% | |
| Return on equity | -22.2% | -544.3% | -55.5% | -649.9% | -59.6% | |
| Return on invested capital | -13.9% | -69.3% | -63.0% | -59.8% | -30.4% | |
| Return on capital employed | -14.1% | -82.3% | -63.5% | -60.3% | -30.6% | |
| Earnings yield | -0.7% | -23.4% | -16.7% | -20.8% | -9.7% | |
| Free cash flow yield | -0.6% | -24.6% | -48.2% | -16.0% | -2.1% | |
| Capex / Op. cash flow | 153.9% | -42.6% | -14.9% | -15.2% | -163.3% | |
| Capex / Depreciation | 95.7% | 232.4% | 107.9% | 136.9% | 189.5% | |
| Capex / Sales | 11.9% | 43.4% | 28.6% | 25.9% | 18.3% | |
| SG&A / Sales | 68.7% | 113.3% | 182.8% | 180.4% | 95.8% | |
| R&D / Sales | 42.0% | 121.2% | 168.7% | 207.7% | 152.6% | |
| Stock comp / Sales | 9.1% | 15.8% | 30.5% | 34.8% | 22.4% | |
| Intangibles / Total assets | 18.7% | 17.5% | 13.2% | 14.4% | 19.1% | |
| Days sales outstanding | 60d | 42d | 53d | 56d | 44d | |
| Days payables outstanding | 876d | 1109d | 1329d | 1428d | 1448d | |
| Operating cycle | 267d | 335d | 353d | 429d | 743d | |
| Cash conversion cycle | -609d | -775d | -975d | -999d | -705d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+148.0%EV / Sales ▲+0.8%EV / EBITDA ▲+2638.6%EV / Op. cash flow ▲+103.687Earnings yield ▲+0.226
Profitability
Return on equity ▲+5.220Return on assets ▲+0.499Return on invested capital ▲+0.553Return on capital employed ▲+0.682Operating ROA ▲+0.364Income quality ▼-2.220Tax burden ▼-0.485
Efficiency
Days sales outstanding ▲+17.157Days payables outstanding ▼-233.714Operating cycle ▼-67.663Cash conversion cycle ▲+166.052Capex / Sales ▼-0.316R&D / Sales ▼-0.793
Balance-sheet strength
Current ratio ▲+0.661Net debt / EBITDA ▲+11.899Working capital ▲+61710000.000Invested capital ▲+65818000.000Intangibles / Total assets ▲+0.012
Change over 5 years
Valuation
Market cap ▲+83.5%EV / Sales ▼-49.9%EV / EBITDA ▲+1648.9%EV / Op. cash flow ▲+228.515Earnings yield ▲+0.089
Profitability
Return on equity ▲+0.374Return on assets ▲+0.190Return on invested capital ▲+0.164Return on capital employed ▲+0.165Operating ROA ▲+0.183Income quality ▼-1.547Tax burden ▼-0.312
Efficiency
Days sales outstanding ▲+15.544Days payables outstanding ▼-572.243Operating cycle ▼-476.171Cash conversion cycle ▲+96.072Capex / Sales ▼-0.065R&D / Sales ▼-1.106
Balance-sheet strength
Current ratio ▼-1.960Net debt / EBITDA ▲+11.130Working capital ▼-181078000.000Invested capital ▼-236066000.000Intangibles / Total assets ▼-0.004
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-19 Travere Therapeutics: Valuation Suggests A Buy Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI''s commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.
- 2026-08-19 Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum HONG KONG, Aug 19, 2026 - (ACN Newswire) - Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered
- 2026-08-18 Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.
- 2026-08-14 Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX Bank of America Corp DE lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) by 27.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,345,111 shares of the company''s stock after selling 517,244 shares
- 2026-08-12 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its common stock. These inducement RSUs are subject to the terms of Travere''s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as.
- 2026-08-06 Travere Therapeutics Q2 Earnings: Why I''m Downgrading To Hold (Again) Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risks and valuation concerns. Filspari''s Q2 net sales surged 96% YoY to $141M, but $3B+ peak sales guidance faces new competition in IgAN and FSGS markets. TVTX''s pipeline expansion with civorebrutinib and pegtibatinase targets rare kidney and metabolic diseases, but both remain early-stage with uncertain timelines.
- 2026-08-06 Empowered Funds LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX Empowered Funds LLC boosted its holdings in Travere Therapeutics, Inc. (NASDAQ: TVTX) by 2,719.8% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,820 shares of the company''s stock after purchasing an additional 81,812 shares during the quarter. Empowered Funds LLC owned
- 2026-08-05 Travere Therapeutics to Participate at Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity''s 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026 Citi 2026 Biopharma Back to School Conference Wednesday, September 9, 2026 2026 Cantor Global Healthcare Conference Presenting on Thursday, Septe.
- 2026-08-04 Travere Therapeutics Q2 Earnings Call Highlights Travere Therapeutics NASDAQ: TVTX reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental glomerulosclerosis, or FSGS.
- 2026-08-04 Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript